Critical Evaluation of the Off-Label Indication and of the Risks Associated to the Use of Multi-Dose Vials on the Treatment of Age-Related Macular Degeneration

Brazilian Journal of Pharmaceutical Sciences - Brazil
doi 10.1590/s1984-82502011000100006
Full Text
Abstract

Available in full text

Date
Authors
Publisher

FapUNIFESP (SciELO)

Related search

Off-Label Use of Bevacizumab for Wet Age-Related Macular Degeneration in Europe

Graefe's Archive for Clinical and Experimental Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2019English

Risks of Age Related Macular Degeneration and Led Lighting

Health Risk Analysis
Health PolicyPublic HealthOccupational HealthEnvironmentalHealth Informatics
2017English

Treatment of Age-Related Neovascular Macular Degeneration: The Patient’s Perspective

Graefe's Archive for Clinical and Experimental Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2017English

Risks of Age Related Macular Degeneration and Led Lighting

Health Risk Analysis
Health PolicyPublic HealthOccupational HealthEnvironmentalHealth Informatics
2017English

Patient Preferences in the Treatment of Neovascular Age-Related Macular Degeneration

Ophthalmology
Ophthalmology
2016English

Prevention and Treatment of Age-Related Macular Degeneration

Prescriber
Pharmacology
2017English

Brolucizumab: Evidence to Date in the Treatment of Neovascular Age-Related Macular Degeneration

Clinical Ophthalmology
Ophthalmology
2019English

New Molecular Targets for the Treatment of Neovascular Age-Related Macular Degeneration

Translational Medicine Reports
2017English

Profile of Conbercept in the Treatment Of neovascular Age-Related Macular Degeneration

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy